China HIV Therapeutics Market Analysis Report [2022-30] I Insights10

China HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the China HIV therapeutics market will reach a value of $1.54 Bn from $1.11 Bn in 2022, growing at a CAGR of 4.2% during 2022-2030. The market is primarily dominated by local players such as Beijing Minhai Biotechnology, Jiangsu Hengrui Medicine, and Sichuan Kelun Pharmaceutical. The market is driven by innovation in research and development, increasing prevalence and reimbursement policies. The HIV therapeutics market in China is segmented by type, product, geography, end user, and distribution channel.

ID: IN10CNPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Dr. Vishwa Modhia

Buy Now

China HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the China HIV therapeutics market will reach a value of $1.54 Bn from $1.11 Bn in 2022, growing at a CAGR of 4.2% during 2022-2030.

Antiretroviral therapy (ART) for those in need is one of the significant efforts the Chinese government has made to combat the HIV/AIDS epidemic in the nation. ART is offered by the National Center for AIDS/STD Control and Prevention (NCAIDS) through a nationwide network of hospitals and clinics.

Blood donations, prostitution, and intravenous drug use are primarily to blame for the rise in AIDS cases in China. In China, the incidence of AIDS was 4.27 per 100,000 people in 2021. In China, 9,62,809 HIV-positive individuals are aware of their status as of 2019. By the end of 2019, 95.7% of pregnant women in China who tested positive for HIV were taking antiretroviral medications (ARVs).

china HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers Analysis

As China's younger generation is becoming increasingly liberal, so are attitudes toward premarital sex. This change is reflected in the number of new HIV diagnoses in people aged 15–24 years doubling between 2008 and 2015, with MSM making up 81.6% of new transmissions. Social stigma and a scarcity of proper sexual health education present formidable barriers to stopping the HIV epidemic.

China's healthcare policies have remained steadfast in their commitment to ensuring that everyone has access to HIV medication, beginning with the Four Frees and One Care policy put in place in 2003. Since 2014, 99% of China's HIV responses have been domestically funded.

Market Restraints

In China, sexual health education has lagged behind healthcare reforms. It is not a requirement for the curriculum in schools. This may limit the market for HIV therapeutics in China's development. Although low-cost and free antiretroviral medications are a blessing, HIV positivity is still strongly stigmatized in China.

Competitive Landscape

Key Players

Sino Biopharmaceutical (CHN)
Jiangsu Hengrui Medicine (CHN)
China National Biotech Group (CNBG) (CHN)
Shanghai Fosun Pharmaceutical (CHN)
Beijing Minhai Biotechnology (CHN)
Sichuan Kelun Pharmaceutical (CHN)
GlaxoSmithKline
Janssen Pharmaceuticals
Gilead
AbbVie

Notable Recent Updates

December 2020: The pre-exposure prophylaxis indication for Truvada has been approved by the China National Medical Products Administration (NMPA), according to a statement from Gilead Sciences. In order to lower the risk of contracting HIV through sexual contact, Truvada for PrEP is recommended in China in conjunction with safer sex practices.

Healthcare Policies and Reimbursement Scenarios

The National AIDS Control Organisation (NACO), established in 1992 is a division of China's Ministry of Health and Family Welfare that provides leadership to HIV/AIDS control programs in China through 35 HIV/AIDS Prevention and Control Societies and is "the nodal organization for the formulation of policy and implementation of programs for prevention and control of HIV/AIDS in China.

Since 2014, 99% of China's HIV responses have been funded domestically. According to a National Health and Family Planning Commission policy, free antiretroviral medication has been provided to all Chinese citizens with HIV since June 2016. Prior to 2006, the nation's HIV/AIDS prevention and treatment plan only applied to the poor in rural and urban areas.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.